PDL1 expression, high tumor mutational burden (≥ 10 mutations/megabase), and high microsatellite instability (MSI-H) are well known biomarkers that are associated with improved outcomes with immunotherapy [80–84]. This evidence concerns the gene CD274 and neoplasm.